Elizabeth Olek

Elizabeth Olek

Direttore Tecnico/Scientifico/R&S presso KRONOS BIO, INC.
61 anni
Health Technology
Consumer Services
Commercial Services

Profilo

Elizabeth A. Olek currently works at Kronos Bio, Inc., as Senior Vice President-Clinical Development.
Dr. Olek also formerly worked at Genetics Institute LLC, as Director-Clinical Research from 1998 to 2002, InterMune, Inc., as Director-Clinical Research from 2003 to 2004, Novartis Pharmaceuticals Corp., as Global Brand Medical Director from 2005 to 2007, Wyeth Research, as Director-Clinical Research from 1998 to 2002, Loxo Oncology, Inc., as Executive Director-Clinical Research from 2019 to 2022, and Achillion Pharmaceuticals, Inc., as Chief Medical Officer & SVP-Clinical Development from 2011 to 2012.
Dr. Olek received her graduate degree from Boston University, undergraduate degree from the University of the Sciences in Philadelphia, and doctorate degree from Philadelphia College of Osteopathic Medicine.

Posizioni attive di Elizabeth Olek

SocietàPosizioneInizio
KRONOS BIO, INC. Direttore Tecnico/Scientifico/R&S -

Precedenti posizioni note di Elizabeth Olek

SocietàPosizioneFine
LOXO ONCOLOGY INC Corporate Officer/Principal 01/02/2022
ACHILLION PHARMACEUTICALS, INC. Direttore Tecnico/Scientifico/R&S 18/06/2012
Corporate Officer/Principal 01/11/2007
INTERMUNE INC Direttore Tecnico/Scientifico/R&S 01/07/2004
Direttore Tecnico/Scientifico/R&S 01/12/2002
Vedi nel dettaglio l'esperienza di Elizabeth Olek

Formazione di Elizabeth Olek

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

60

Relazioni di 1° grado

10

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private10

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Commercial Services

Consumer Services

Health Technology

Health Technology

  1. Mercati
  2. Insiders
  3. Elizabeth Olek
40% di sconto: I migliori strumenti riservati agli abbonati per identificare i migliori investimenti di domani!
g
:
:
ENTRA ORA